NYSE:MAIA
MAIA Biotechnology, Inc.
A clinical-stage biotech firm focused on developing next-generation oncology therapeutics with a substantial cash runway and significant R&D investment.
Key Metrics
Investment Thesis
Bull Case
Investors may consider MAIA if they believe in the transformative potential of its oncology pipeline and view the current cash balance as sufficient to reach key clinical milestones without immediate dilution. The company's ability to generate positive net change in cash despite a negative operating cash flow suggests effective capital management or successful financing events.
Bear Case
The stock carries extreme risk due to zero revenue, a deep retained earnings deficit of $87.2M, and accelerating annual losses from $-15.8M in 2022 to $-23.3M in 2024. Without an imminent approval or partnership deal, the company faces a high probability of insolvency or severe equity dilution.
About MAIA Biotechnology, Inc.
MAIA Biotechnology, Inc. is a clinical-stage biopharmaceutical company developing novel therapeutics for oncology and other serious diseases, primarily serving the US market through its pipeline of investigational drugs. The company currently has no commercial revenue, relying on strategic partnerships and financing to fund its research and development efforts in cancer immunotherapy and cellular therapies.
Analysis
Management Discussion
The company reported a net loss of $23.3M for the latest period, driven by $10.0M in research and development costs and $6.9M in general and administrative expenses. Despite these losses, cash flow from financing activities of $18.2M helped increase total cash and equivalents to $9.6M, while non-cash adjustments totaling $8.5M reflect the significant value added by share-based compensation.
Industry Overview
The clinical-stage biotechnology industry is characterized by high failure rates and long development cycles, where value is derived from successful drug approvals rather than current sales. Companies in this space typically operate with negative earnings and rely heavily on venture capital or public markets to fund expensive research and development programs.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Revenue | $0 | $0 | $0 |
| Cost of Revenue | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 |
| Operating Expenses | $16.2M | $20.2M | $17.0M |
| Operating Income | $-16.2M | $-20.2M | $-17.0M |
| R&D | $8.9M | $11.1M | $10.0M |
| G&A | $6.1M | $9.1M | $6.9M |
| Stock-Based Comp | $2.3M | $3.1M | $1.9M |
| Other OpEx | $1.1M | $0 | $0 |
| Non-Operating Income | $376.2K | $382.4K | $-6.3M |
| Interest Expense | $7.0K | $6.9K | $57 |
| Interest Income | $1.9K | $34.5K | $318.4K |
| Pre-Tax Income | $-15.8M | $-19.8M | $-23.3M |
| Income Tax | $-30.7K | $-27.1K | $-45.3K |
| Continuing Ops | $-15.8M | $-19.8M | $-23.3M |
| Discontinued Ops | $0 | $0 | $0 |
| Net Income | $-15.8M | $-19.8M | $-23.3M |
| Minority Interest | $0 | $0 | $0 |
| Net to Common | $-15.8M | $-19.8M | $-23.3M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Current Assets | $11.8M | $7.6M | $10.2M |
| Cash & Equivalents | $0 | $0 | $0 |
| Prepaid Expenses | $554.3K | $268.7K | $473.8K |
| Other Current Assets | $11.3M | $7.3M | $9.7M |
| Long-Term Assets | $214.0K | $2.8K | $2.8K |
| Total Assets | $12.0M | $7.6M | $10.2M |
| Current Liabilities | $3.3M | $4.9M | $3.8M |
| Accounts Payable | $1.2M | $1.6M | $1.5M |
| Other Current Liab | $0 | $0 | $0 |
| Long-Term Liabilities | $245.3K | $2.2M | $2.7M |
| Total Liabilities | $3.5M | $7.1M | $6.5M |
| Shareholders' Equity | $8.5M | $477.5K | $3.6M |
| Paid-In Capital | $52.7M | $64.5M | $90.9M |
| Retained Earnings | $-44.2M | $-64.0M | $-87.2M |
| AOCI | $-16.0K | $-16.3K | $-30.6K |
| Total L&E | $12.0M | $7.6M | $10.2M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Net Income (CFO) | $-15.8M | $-19.8M | $-23.3M |
| Non-Cash Adjustments | $2.2M | $4.5M | $8.5M |
| Working Capital Changes | $1.9M | $2.2M | $-902.7K |
| Cash from Operations | $-11.7M | $-13.1M | $-15.7M |
| Cash from Investing | $0 | $0 | $0 |
| Cash from Financing | $12.0M | $9.3M | $18.2M |
| FX Effect | $-4.4K | $-117 | $-21.5K |
| Net Change in Cash | $376.6K | $-3.8M | $2.5M |
| Beginning Cash | $10.6M | $11.0M | $7.2M |
| Ending Cash | $11.0M | $7.2M | $9.6M |
Frequently Asked Questions
How does MAIA Biotechnology, Inc. make money?
The company's financial profile indicates operations are centered entirely on Research & Development, specifically Oncology Drug Discovery and Clinical Trials, as evidenced by $10.0M in dedicated R&D expenses against zero commercial revenue.
What are the main risks for MAIA?
Complete dependence on external capital raises due to lack of revenue streams, potential failure of clinical trials for its drug candidates, and the risk of dilution from equity issuances to fund ongoing $17.0M in operating expenses.
What is MAIA's competitive advantage?
Access to proprietary drug candidates in high-value oncology indications, a strategic cash position of $9.6M providing operational runway, and a management team capable of securing substantial financing rounds ($18.2M from financing activities).
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.